Targeted immunotherapies in systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 32, Issue SUPPL.81, 2014, Pages

  Avouac, Jérôme ^a   Allanore, Yannick ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Immunotherapies; Systemic sclerosis

Indexed keywords

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; SCLERODERMA, SYSTEMIC;

EID: 84898777391     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. ROMANO E, MANETTI M, GUIDUCCI S et al.: The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 2011; 29 (Suppl. 65): S75-86.
2. MAUVIEL A, DAIREAUX M, REDINI F et al.: Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett 1988; 236: 47-52.
3. VERRECCHIA F, WAGNER EF, MAUVIEL A: Distinct involvement of the Jun-N-terminal kinase and NF-kappaB pathways in the repression of the human COL1A2 gene by TNF-alpha. EMBO reports 2002; 3: 1069-74.
4. DAYER JM, BEUTLER B, CERAMI A: Cachectin/ tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163-8.
5. ITO A, SATO T, IGA T et al.: Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett 1990; 269: 93-5.
6. THEISS AL, SIMMONS JG, JOBIN C et al.: Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 2005; 280: 36099-109.
7. SULLIVAN DE, FERRIS M, POCIASK D et al.: Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol 2005; 32: 342-9.
8. McCULLOCH CA, KNOWLES GC: Deficiencies in collagen phagocytosis by human fibroblasts in vitro: a mechanism for fibrosis? J Cell Physiol 1993; 155: 461-71
9. CHOU DH, LEE W, McCULLOCH CA: TNF-alpha inactivation of collagen receptors: implications for fibroblast function and fibrosis. J Immunol 1996; 156: 4354-62.
10. AVOUAC J, FURNROHR BG, TOMCIK M et al.: Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011; 63: 800-9.
11. KOCA SS, ISIK A, OZERCAN IH et al.: Effectiveness of etanercept in bleomycin-induced experimental scleroderma. Rheumatology (Oxford) 2008; 47: 172-5.
12. PIGUET PF, COLLART MA, GRAU GE et al.: Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990; 344: 245-7.
13. PIGUET PF, VESIN C: Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7: 515-8.
14. ALLANORE Y, DEVOS-FRANCOIS G, CARAMELLA C et al.: Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006; 65: 834-5.
15. SAITO S, KASTURI K, BONA C: Genetic and immunologic features associated with scleroderma-like syndrome of TSK mice. Curr Rheumatol Rep 1999; 1: 34-7.
16. SAITO E, FUJIMOTO M, HASEGAWA M et al.: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002; 109: 1453-62.
17. ASANO N, FUJIMOTO M, YAZAWA N et al.: B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004; 165: 641-50.
18. ODAKA M, HASEGAWA M, HAMAGUCHI Y et al.: Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clin Exp Immunol 2010; 159: 176-84.
19. HASEGAWA M, HAMAGUCHI Y, YANABA K et al.: B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006; 169: 954-66.
20. MATSUSHITA T, FUJIMOTO M, HASEGAWA M et al.: Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007; 34: 2056-62.
21. KOMURA K, YANABA K, HORIKAWA M et al.: CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008; 58: 3574-84.
22. MUANGCHANT C, POPE JE: The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. Clin Exp Rheumatol 2013; 31: 122-34.
23. KAWAGUCHI Y, HARA M, WRIGHT TM: Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103: 1253-60.
24. KADONO T, KIKUCHI K, IHN H et al.: Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998; 25: 296-301.
25. ALLANORE Y, SAAD M, DIEUDE P et al.: Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 2011; 7: e1002091.
26. ATAMAS SP: Complex cytokine regulation of tissue fibrosis. Life Sci 2002; 72: 631-43.
27. KITABA S, MUROTA H, TERAO M et al.: Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012; 180: 165-76.
28. LE HUU D, MATSUSHITA T, JIN G et al.: IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol 2012; 132: 2752-61.
29. FRECH TM, SHANMUGAM VK, SHAH AA et al.: Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 2013; 31: 166-71.
30. YOSHIZAKI A, YANABA K, OGAWA A et al.: Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011; 63: 3575-85.
31. DISTLER JH, JUNGEL A, HUBER LC et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22.
32. HINCHCLIFF M, HUANG CC, ISHIDA W et al.: Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. Clin Exp Rheumatol 2012; 30 (Suppl. 71): S86-96.
33. AKHMETSHINA A, VENALIS P, DEES C et al.: Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
34. DISTLER JH, DISTLER O: Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology (Oxford) 2009; 48: 2-4.
35. LAM GK, HUMMERS LK, WOODS A et al.: Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007; 34: 1636-7.
36. DENTON CP, ENGELHART M, TVEDE N et al.: An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009; 68: 1433-9.
37. RAMOS-CASALS M, PEREZ-ALVAREZ R, PEREZ-de-LIS M et al.: Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011; 124: 386-94.
38. OMAIR MA, PHUMETHUM V, JOHNSON SR: Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol 2012; 30: S55-9.
39. DISTLER J, JORDAN S, AIRO P et al.: Is there a role for TNFα antagonists in the treatment of SSc? - EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol 2011; 29 (Suppl. 65): S40-5.
40. SMITH V, Van PRAET JT, VANDOOREN B et al.: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010; 69: 193-7.
41. SMITH V, PIETTE Y, Van PRAET JT et al.: Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013; 40: 52-7.
42. LAFYATIS R, KISSIN E, YORK M et al.: B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60: 578-83.
43. BOSELLO S, De SANTIS M, LAMA G et al.: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
44. DAOUSSIS D, LIOSSIS SN, TSAMANDAS AC et al.: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49: 271-80.
45. DAOUSSIS D, LIOSSIS SN, TSAMANDAS AC et al.: Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30 (Suppl. 71): S17-22.
46. JORDAN S, DISTLER J, MAURER B et al.: Rituximab improves skin fibrosis and prevents worsening of lung function in patients with systemic sclerosis in the EUSTAR cohort. Ann Rheum Dis 2012; 71: 403.
47. SHIMA Y, KUWAHARA Y, MUROTA H et al.: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010; 49: 2408-12.
48. ELHAI M, MEUNIER M, MATUCCI-CERINIC M et al.: Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013; 72: 1217-20.
49. SPIERA RF, GORDON JK, MERSTEN JN et al.: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70: 1003-9.
50. POPE J, McBAIN D, WATSON S et al.: Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind- placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011; 63: 3547-51.
51. PREY S, EZZEDINE K, DOUSSAU A et al.: Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012; 167: 1138-44.
52. BECKER MO, BRUCKNER C, SCHERER HU et al.: The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann Rheum Dis 2011; 70: 1340-1.